Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stake Lessened by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 55.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,050 shares of the biotechnology company's stock after selling 52,815 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Sarepta Therapeutics were worth $4,151,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. International Assets Investment Management LLC increased its stake in Sarepta Therapeutics by 9,382.5% during the 4th quarter. International Assets Investment Management LLC now owns 11,379 shares of the biotechnology company's stock worth $1,097,000 after buying an additional 11,259 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Sarepta Therapeutics by 351.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,824 shares of the biotechnology company's stock valued at $1,044,000 after purchasing an additional 8,427 shares during the last quarter. Fifth Third Bancorp increased its position in shares of Sarepta Therapeutics by 1,215.8% in the 4th quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company's stock valued at $96,000 after purchasing an additional 924 shares during the last quarter. Handelsinvest Investeringsforvaltning purchased a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $302,000. Finally, DMC Group LLC increased its position in shares of Sarepta Therapeutics by 15.0% in the 4th quarter. DMC Group LLC now owns 3,793 shares of the biotechnology company's stock valued at $366,000 after purchasing an additional 496 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT traded down $1.02 during trading hours on Tuesday, reaching $117.29. 592,907 shares of the company's stock were exchanged, compared to its average volume of 1,002,834. The firm has a market capitalization of $11.01 billion, a price-to-earnings ratio of -19.17 and a beta of 0.94. The company has a 50-day moving average of $127.13 and a 200 day moving average of $110.34. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company had revenue of $396.80 million during the quarter, compared to analysts' expectations of $387.18 million. During the same quarter last year, the business earned ($1.24) EPS. The business's revenue was up 53.6% on a year-over-year basis. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on SRPT shares. Wedbush reissued an "outperform" rating and issued a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Cantor Fitzgerald reissued a "neutral" rating and issued a $128.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Needham & Company LLC dropped their price objective on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a "buy" rating on the stock in a research report on Thursday, February 29th. Royal Bank of Canada increased their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an "outperform" rating in a research report on Thursday, February 29th. Finally, TheStreet upgraded shares of Sarepta Therapeutics from a "d" rating to a "c-" rating in a report on Monday, March 4th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $158.38.

Insider Transactions at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 761 shares of the firm's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Kathryn Jean Boor sold 761 shares of the firm's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Bilal Arif sold 2,000 shares of the firm's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the sale, the insider now owns 26,836 shares of the company's stock, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,096 shares of company stock worth $2,739,419. Company insiders own 7.40% of the company's stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.